Form 4: Pliant Therapeutics CEO, Bernard Coulie, Reports Stock and Option Transactions

Pliant Therapeutics CEO, Bernard Coulie, acquired 162,500 shares of common stock and 325,000 stock options, while also reporting indirect ownership of 409,317 shares through a family trust.

Summary

• Bernard Coulie, CEO of Pliant Therapeutics, reported acquiring 162,500 shares of common stock and 325,000 stock options on January 23, 2025.
• The 162,500 shares were granted as restricted stock units that vest in three equal annual installments starting January 16, 2025.
• The 325,000 stock options vest monthly over four years, starting January 1, 2025, and have an exercise price of $11.14.
• Coulie also reported indirect ownership of 409,317 shares held by The Coulie/Leyman Family Trust, for which he disclaims beneficial ownership except for his pecuniary interest.
• A power of attorney was executed on January 22, 2025, authorizing Jennifer Woo, Keith Cummings, Johannes (Hans) Hull, and Mike Ouimette to file SEC forms on Coulie's behalf.

Sentiment

Score: 7

Explanation: The document reflects standard insider transactions, which are generally neutral to positive. The CEO's acquisition of stock and options suggests confidence in the company's future.

Positives

• The acquisition of stock and options by the CEO could be seen as a positive sign of confidence in the company's future.
• The vesting schedule of the restricted stock units and options aligns the CEO's interests with the long-term performance of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the holdings and transactions of key personnel.

Comparison to Industry Standards

• The vesting schedules for the restricted stock units and stock options are typical for executive compensation packages in the biotechnology industry.
• The reporting of indirect ownership through a family trust is also a common practice among executives.

Stakeholder Impact

• The transactions may be viewed positively by shareholders as they indicate the CEO's alignment with the company's success.
• The vesting schedules of the stock and options could incentivize the CEO to focus on long-term value creation.

Key Dates

Keywords

Pliant Therapeutics, Bernard Coulie, stock options, restricted stock units, beneficial ownership, SEC Form 4, insider trading, power of attorney